Urology
Volume 59, Issue 6 , Pages 811-815 , June 2002

Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions

  • Claus G Roehrborn

      Affiliations

    • Corresponding Author InformationReprint requests: Claus G. Roehrborn, M.D., Department of Urology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, J8-130, Dallas, TX 75390-9110USA
    • Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

Received 12 February 2002 ,Revised 28 February 2002 ,Accepted 28 February 2002.

References 

  1. Jacobsen SJ, Jacobson DJ, Girman CJ, et al.  Natural history of prostatism (risk factors for acute urinary retention). J Urol. 1997;158:481–487
  2. McConnell JD, Bruskewitz R, Walsh P, et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–563
  3. Roehrborn CG, Brusketwitz R, Nickel GC, et al.  Urinary retention in patients with BPH treated with finasteride or placebo over 4 years (characterization of patients and outcomes). Eur Urol. 1999;37:528–536
  4. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al.  Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 1991;337:1457–1461
  5. Somers WJ, Mora MJ, Mason MF, et al.  The natural history of benign prostatic hypertrophy (incidence of urinary retention and significance of AUA symptom score). (abstract) J Urol. 1996;155(5 suppl):586A
  6. Debruyne FMJ, Jardin A, Collol D, et al.  Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 1998;34:169–175
  7. Kirby R, Altwein JE, Bartsch G. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. (abstract) J Urol. 1999;161:266
  8. Michel MC. Benign prostatic obstruction complications and need for surgery. Drugs Today. 2000;36(suppl F):11–13
  9. Michel MC. Meta-analysis of alpha-blocker effects on acute urinary retention (AUR). (abstract) Eur Urol. 2001;39(suppl 5):97
  10. Michel MC, Goepel M. Do α-blockers affect the progression of benign prostatic hyperplasia. (abstract)? J Urol. 2001;165:379
  11. Andersen JT, Nickel JC, Marshall VR, et al.  Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997;49:839–845
  12. Andersen JT, Ekman P, Wolf H, et al.  Scandinavian BPH Study Group   Can finasteride reverse the progress of benign prostatic hyperplasia? A 2-year placebo-controlled study. Urology. 1995;46:631–637
  13. Nickel JC, Fradet Y, Boake RC, et al.  PROSPECT Study Group   Efficacy and safety of finasteride therapy for benign prostatic hyperplasia (results of a 2-year randomized controlled trial (the PROSPECT study)). Can Med Assoc J. 1996;155:1251–1259
  14. Marberger MJ  PROWESS Study Group . Long-term effects of finasteride in patients with benign prostatic hyperplasia (a double-blind, placebo-controlled, multicenter study). Urology. 1998;51:677–686
  15. Roehrborn CG, Oesterling JE, Auerbach S, et al.  Hytrin Community Assessment Trial Study   A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology. 1999;47:159–168
  16. Michel MC, Bressel H-U, Goepel M, et al.  A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol. 1999;48:871P–891P
  17. McConnell JD, Miller G, Lieber M, et al.  Baseline patient characteristics in the NIH BPH trial. (abstract) J Urol. 1997;157:313

PII: S0090-4295(02)01649-7

Urology
Volume 59, Issue 6 , Pages 811-815 , June 2002

Article Tools

* Image Usage & Resolution